PERTH, Australia – With the approval of cystic fibrosis treatment Bronchitol (mannitol), Sydney-based Pharmaxis Ltd. joins a small group of elite Australian biotech companies to take their drugs all the way to FDA approval. Read More
DUBLIN – Kiadis Pharma BV has parlayed its €31.9 million (US$37.2 million) stock-based acquisition of Cytosen Therapeutics Inc. last year, which involved an initial outlay of just €14.5 million worth of shares, into a €308 million payday with Sanofi SA. Read More
Jounce Therapeutics Inc. has quit enrolling Emerge, an open-label phase II study of its inducible T-cell co-stimulator agonist, vopratelimab, the company’s most advanced candidate. Read More
LONDON – Former CEO of Novartis AG Joe Jimenez is emerging back into the limelight as founder and managing director of Aditum Bio, a new $135 million venture capital fund set up to create five to six companies to take forward early stage compounds in-licensed from pharma. Read More
A multimillion dollar windfall for Icosavax Inc. will help allow the company to launch a COVID-19 vaccination program using its virus-like particle candidate (VLP), IVX-411, that displays the SAR-CoV-2 receptor-binding domain. Read More
The dramatic increase in COVID-19 infections in Europe and the U.S., combined with information overload surrounding the lead up to the Nov. 3 contentious U.S. presidential election, was more than enough to send investors to the sidelines in October. Read More
LONDON – People infected with COVID-19 are likely to have T-cell immunity six months after contracting the virus, according to a U.K. study of 100 subjects who had an asymptomatic or mild to moderate infection. Read More
October brought another burgeoning swell of pandemic news with the U.S. granting its first FDA approval for a COVID-19 therapy, a promising vaccine candidate reaching full enrollment in phase III, and the stoppage of several trials due to safety signals. Read More
HONG KONG – Haihe Pharmaceutical Co. Ltd. has outsourced the China rights to its non-opioid analgesics candidates, RMX-1001 and RMX-1002, to 3D Biomedicine Science & Technology Co. Ltd. in the latest collaboration between the two companies. Read More
The latest global regulatory news, changes and updates affecting biopharma, including: Canada prepares for resurgence of COVID-19 shortages; Russia sets drug pricing structure. Read More
New hires and promotions in the biopharma industry, including: Acousia, Caladrius, Cormedix, Eagle, Horizon, Freeline, Mission, Mogrify, Oryzon, Rallybio, Silence, X4. Read More
Biopharmas raising money in public or private financings, including: Carsgen, Corlieve, Cure, Erytech, Mirati, Novartis, Population Health, Regenxbio. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: CSL, DBV, Chiesi, Imugene, Innocare, Innovation, Janssen, Neuraly, Pharmaxis, Polarityte, Poseida, Provention, Roche, Senhwa, Taigen. Read More